Allspring Global Investments’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Allspring Global Investments’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-753	Closed	-$835	–	2988
2022 Q4	$835	Sell	753 -17	-2%	-$24	﹤0.01%	2891
2022 Q3	$1K	Hold	770	–	–	﹤0.01%	2868
2022 Q2	$2K	Sell	770 -72,168	-99%	-$351K	﹤0.01%	2655
2022 Q1	$495K	Sell	72,938 -5,756	-7%	-$41K	﹤0.01%	2223
2021 Q4	$657K	Buy	+78,694	New	+$648K	﹤0.01%	2176

Other funds holding JNCE

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

ACM

Ardent Capital Management Cincinnati, Ohio $241M AUM 23.63% 1-Year Est. Return

Allspring Global Investments's JNCE Position: Q1 2023 in Review

Allspring Global Investments sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2023, closing a stake of 753 shares — an estimated $835 sold.

Allspring Global Investments first reported a position in JNCE in Q4 2021 and held it in 5 quarters. The position peaked at $657K in Q4 2021. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.

Allspring Global Investments reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Allspring Global Investments sold 753 Jounce Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $835.
Allspring Global Investments first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
Allspring Global Investments's Jounce Therapeutics, Inc. Common Stock position peaked at $657K in Q4 2021.
84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Allspring Global Investments's 13F filing for Q1 2023, filed 13 Apr 2023.